Evaluation of SPf66 malaria vaccine efficacy in Brazil

American Journal of Tropical Medicine and Hygiene

Volumn 58, Issue 3, 1998, Pages 378-385

  Urdaneta, Margarita ^a   Prata, Aluizio ^b,e   Struchiner, Claudio J ^a   Tosta, C Eduardo ^c   Tauil, Pedro ^c   Boulos, Marcos ^d  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Medicina Tropical   (Brazil)

^c UNIVERSITY OF BRASILIA   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e Faculdade Med Triangulo Mineiro   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; FANSIDAR; IMMUNOGLOBULIN G ANTIBODY; MALARIA VACCINE; MEFLOQUINE; PLACEBO; QUININE; TETRACYCLINE;

ADOLESCENT; ADULT; ARTICLE; BRAZIL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENDEMIC DISEASE; FEMALE; HUMAN; MALARIA; MALE; PHASE 3 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINATION;

EID: 0031922809     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.1998.58.378     Document Type: Article

References (31)

1. Amador R, Moreno A, Valero V, Murillo L, Mora AL, Rojas M, Rocha C, Salcedo M, Guzman Espejo F, Nunez F, Patarroyo ME, 1992. The first field trials of the chemically synthesized malaria vaccine SPf66: safety, immunogenicity and protectivity. Vaccine 10: 179-184.
2. Amador R, Moreno A, Murillo LA, Sierra O, Saavedra D, Rojas M, Mora AL, Rocha CL, Alvarado F, Falla JC, Orozco M, Coronell C, Ortega N, Molano A, Velaquez JF, Valero MV, Franco L, Guzman F, Salazar LM, Espejo F, Mora E, Farfan R, Zapata N, Rosas J, Calvo JC, Castro J, Quinones T, Nunez F, Patarroyo ME, 1992. Safety and immunogenicity of the synthetic malaria vaccine SPf66 in a large field trial. J Infect Dis 166: 139-144.
3. Valero MV, Amador LR, Galindo C, Figueroa J, Bello MS, Murillo LA, Mora AL, Patarroyo G, Rocha CL, Rojas M, Aponte JJ, Sarmiento LE, Lazada DM, Coronell CG, Ortega NM, Rosas JE, Alonso PL, Patarroyo ME, 1993. Vaccination with SPf66, a chemically synthesized vaccine, against Plasmodium falciparum malaria in Colombia. Lancet 341: 705-710.
4. Sempertegui F, Estrella B, Moscoso J, Piedrahita L, Hernandez D, Gaybor J, Naranjo P, Mancero O, Arias S, Bernal R, Cordova ME, Suarez J, Zicker F, 1994. Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against Plasmodium falciparum infection in a randomized double-blind placebo controlled field trial in an endemic area of Ecuador. Vaccine 12: 337-342.
5. Noya O, Gabaldon Y, Alarcon de Noya B, Borges R, Zerpa N, Urbaez JD, Madonna A, Garrido E, Jimenez MA, Borges RE, Garcia P, Reyes I, Prieto W, Colmenares C, Pabon R, Barraez T, de Caceres LG, Godoy N, Sifontes R, 1994. A population-based clinical trial with the SPf66 synthetic Plasmodium falciparum malaria vaccine in Venezuela. J Infect Dis 170: 396-402.
6. Alonso PL, Smith T, Armstrong Schellenberg JRM, Masanja H, Mwankusye S, Urassa H, Bastos de Azevedo I, Chongela J, Kobero S, Menendez C, Hurt N, Thomas MC, Lyimo E, Weiss NA, Hayes R, Kitua AY, Lopez MC. Kllama WL, Teuscher T, Tanner M, 1994. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 344: 1175-1181.
7. Teuscher T, Armstrong Schellenberg JRM, Bastos de Azevedo I, Hurt N, Smith T. Hayes R, Masanja H, Silva Y, Lopez MC, Kitua A, Kilama W, Tanner M, Alonso PL, 1994. SPf66. a chemically synthesized subunit malaria vaccine, is safe and immunogenic in Tanzanians exposed to intense malaria transmission. Vaccine 12: 328-336.
8. D'Alessandro U, Leach A, Drakely CJ, Bennett S, Olaleye B, Fegan GW, Jawara M, Langeroc P, George MO. Targett GAT, Greenwood BM, 1995. Efficacy trial of malaria vaccine SPf66 in Gambian infants. Lancet 346: 462-467.
9. Nosten F, Luxemburger C, Kyle DE, Ballow WR, Wittes J, Wah E, Chongsuphajaisiddhi T, Gordon DM, White NJ, Sadoff JC, Heppner DG, 1996. Randomized double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Lancet 348: 701-707.
10. Alonso PL, Smith TA, Armstrong-Schellenberg JRM, Kitua AY, Masanja H, Hayes R, Hurt N, Font F, Menendez C, Kilama WL, Tanner M, 1996. Duration of protection and age-dependence of the effects of the SPf66 malaria vaccine in African children exposed to intense transmission of Plasmodium falciparum. J Infect Dis 174: 367-372.
11. World Health Organization, 1994. World malaria situation in 1992. Wkly Epidemiol Rec 43: 317-321.
12. Klein TA, Lima JBP, 1990. Seasonal distribution and biting patterns of Anopheles mosquitoes in Costa Marques, Rondonia, Brazil. J Am Mosq Control Assoc 6: 700-706.
13. Klein TA, Lima JBP, Tada MS, 1991. Comparative susceptibility of anopheline mosquitoes in Rondonia, Brazil to infection by Plasmodium vivax. Am J Trop Med Hyg 45: 463-470.
14. Klein TA, Lima JBP, Tada MS, 1991. Comparative susceptibility of anopheline mosquitoes to Plasmodium falciparum in Rondonia, Brazil. Am J Trop Med Hyg 44: 598-603.
15. Klein TA, Lima JBP, Tang AT, 1991. Biting behavior of Anopheles mosquitoes in Costa Marques, Rondonia, Brazil. Rev Soc Bras Med Trop 24: 13-20.
16. McGreevy PB, Dietze R, Prata A, Hembree SC, 1989. Effects of immigration on the prevalence of malaria in rural areas of the Amazon Basin of Brazil. Mem Inst Oswaldo Cruz 84: 485-491.
17. Prata A, Urdaneta M, McGreevy PB, Shugiro Tada M, 1988. Infrequency of asymptomatic malaria in an endemic area in Amazonas. Brazil. Rev Soc Bras Med Trop 21: 51-54.
18. Urdaneta M, Prata A, Struchiner CJ, Tosta CE, Tauil P, Boulos M, 1996. SPf66 vaccine trial in Brazil: conceptual framework study design and analytical approach. Rev Bras Med Trop 29: 259-269.
19. Prata A, 1992. A eficacia das atuais medidas de controle da malaria: drogas antimalaricas. Rev Soc Bras Med Trop 25 (suppl II): 37-40.
20. World Health Organization, 1988. Report on a Technical Consultation on Research and Support of Malaria Control in the Amazon Basin. Brasilia: World Health Organization, TDR/FIELDMAL/SC/AMAZ/88.
21. Moreno A, Patarroyo ME, 1989. Development of an asexual blood stage malaria vaccine. Blood 74: 537-546.
22. Rocha CL, Murillo LA, Mora AL, Rojas M, Franco L, Cote J, Valero MV, Moreno A, Amador R, Nunez F, Coronell C, Patarroyo ME, 1992. Determination of the immunization schedule for field trials with the synthetic malaria vaccine SPf66. Parasite Immunol 14: 95-109.
23. Urdaneta M, Prata A, Struchiner CJ, Tosta CE, Tauil P, Boulos M, 1996. Safety evaluation of SPf66 malaria vaccine in Brazil. Rev Soc Bras Med Trop 29: 497-501.
24. World Health Organization, 1989. Guidelines for the Evaluation of Plasmodium falciparum Asexual Blood-Stage Vaccines in Populations Exposed to Natural Infection. Geneva: WHO, TDR/MAP/AVE/89.
25. Lopez-Antunano FJ, Schmunis G, 1988. Diagnostics de Malaria. Publicacao Cientifica, No. 512. Washinton, DC: Pan Amercian Health Organization.
26. Kleinbaum DG, Kupper LL, Morgenstein H, 1982. Epidemiologic Research Principles and Quantitative Methods. Belmont, CA: Lifetime Learning Publications.
27. Smith PG, Morrow RH, 1992. Methods for Field Trials of Interventions Against Tropical Diseases. New York: Oxford University Press, 293.
28. Patarroyo ME, Vinasco J, Amador R, Espejo F, Silva Y, Moreno A, Rojas M, Mora AL, Salcedo M, Valero V, Goldberg AK, Kalil J, 1991. Genetic control of the immune response to a synthetic vaccine against Plasmodium falciparum. Parasite Immunol 13: 509-516.
29. Murillo LA, Rocha CL, Mora AL, Kalil J, Goldenberg AC, Patarroyo ME, 1991. Molecular analysis of HLA DR4-β1 gene in malaria vaccinces: typing and subtyping by PCR technique and oligonucleotides. Parasite Immunol 13: 201-210.
30. Murillo LA, Tenjo FA, Clavijo OP, Orozco MA, Sampaio S, Kalil J, Patarroyo ME, 1992. A specific T-cell receptor genotype preference in the immune response to a synthetic Plasmodium falciparum malaria vaccine. Parasite Immunol 14: 87-94.
31. Beck H-P, Felger I, Barker M, Bugawan T, Genton B, Alexander N, Jazwinska E, Erlich H, Alpers M, 1995. Evidence of HLA class II association with antibody response against the malaria vaccine SPf66 in a natural exposed population. Am J Trop Med Hyg 53: 284-288.